safety profile – Page 26 – Communicable Diseases Research

Identification of antiviral antihistamines for COVID-19 repurposing

COVID-19 용도 변경을 위한 항바이러스성 항히스타민제 식별

Article

Published on 2021-01-292022-08-31
Journal: Biochemical and Biophysical Research Communication [Category] SARS, 신약개발, 유전자 메커니즘, 치료제,

Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients

Research

Published on 2021-01-252022-10-29
Journal: Translational Medicine Communications [Category] COVID-19,

[키워드] acute respiratory syndrome affected Antiviral effect approved association caused clinical symptom Computed tomography coronavirus coronavirus disease COVID-19 COVID-19 patient COVID-19 patients death drug Effect effective vaccine evaluate exclusion criteria Infection initial involved Iran lower risk lung mechanical ventilation morbidity Mortality mortality rate pandemic Patient patients patients with COVID-19 patients with COVID19 Pleiotropic effects Prevent propensity score matching Randomized controlled trial recruitment reduce reduced reduction in mortality Regression model repurposing Result retrospective cohort study Retrospective study safety profile SARS-CoV-2 statin statins statistical significance treat Treatment triggered Vaccine were used with COVID-19 wound healing
[DOI] 10.1186/s41231-021-00082-5 PMC 바로가기 [Article Type] Research

Hydroxychloroquine and COVID-19: a Rheumatologist’s Take on the Lessons Learned

Hydroxychloroquine과 COVID-19: 배운 교훈에 대한 류마티스 전문의의 견해

Review

Published on 2021-01-212022-09-11
Journal: Current allergy and asthma reports [Category] 신약개발, 치료제,

[키워드] Antiviral antiviral agent Autoimmune disease Concentration conditions contributing to COVID-19 COVID-19 infection difficulty disease effective endolysosomal exploration Hydroxychloroquine immunomodulation immunomodulatory Infection lesson mechanisms novel SARS-CoV-2 virus other conditions Patient pharmacokinetics potential mechanism Prevent question recent rheumatic disease safety profile SARS-CoV-2 SARS-CoV-2 virus Support target tissue the SARS-CoV-2 virus therapeutic therapeutic effect therapeutic strategy toxicities treat Treatment treatment of COVID-19 use of hydroxychloroquine Variability viral disease
[DOI] 10.1007/s11882-020-00983-9 PMC 바로가기 [Article Type] Review

Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent

오프 타겟 시험관 내 프로파일링은 렘데시비르가 고도로 선택적인 항바이러스제임을 보여줍니다

Article

Published on 2021-01-202022-09-11
Journal: Antimicrobial Agents and Chemotherapy [Category] 치료제,

[키워드] 50% effective concentration addition adenosine aerobic agent Anti-SARS-CoV-2 Activity Antiviral Antiviral agents assays biochemical biochemical assay cells cellular cellular respiration Concentration coronavirus COVID-19 cytotoxicity demonstrated DNA DNA and RNA Effect elicit epithelial cells evaluated Filovirus filoviruses GS-5734 human airway human airway epithelial human airway epithelial cells human cell human cell line human cell lines human cells inhibitor Interaction Last MERS MERS-CoV metabolic conditions metabolite Mitochondria mitochondrial mitochondrial DNA mitochondrial respiration nucleoside nucleoside analogs oxygen polymerases primary cells Profiling protein synthesis ranged RDV reactive oxygen species Remdesivir reported resulting safety profile SARS-CoV SARS-CoV-2 selective selectivity indices target tested Toxicity Treatment triphosphate turn Viral Viral RNA
[DOI] 10.1128/AAC.02237-20 PMC 바로가기 [Article Type] Article

Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis

COVID-19 치료를 위한 Sofosbuvir/daclatasvir 요법: 개별 환자 데이터 메타 분석

Meta-Analysis

Published on 2021-01-192022-09-11
Journal: Journal of Antimicrobial Chemotherapy [Category] 임상, 치료제,

[키워드] 95% CI all-cause mortality Analysis antiviral activity approach Arm ARMS baseline characteristics Characteristics clinical Clinical outcome clinical outcomes clinical recovery clinical trial Combination comparator control arm daclatasvir eight Evidence HCV hospitalized COVID-19 patient hospitalized COVID-19 patients IMPROVE in vitro study inclusion criteria Meta-analysis moderate to severe non-randomized patient data patients patients with moderate Primary outcome Primary outcomes random-effect randomization Randomized Randomized controlled trials regimen risk risk ratio safety profile Sample size SARS-CoV-2 severe COVID-19 significantly lower sofosbuvir sofosbuvir/daclatasvir survival Treatment Trial was used
[DOI] 10.1093/jac/dkaa418 PMC 바로가기 [Article Type] Meta-Analysis

Perinatal Cells: A Promising COVID-19 Therapy?

Bioengineering and Biotechnology

Published on 2021-01-142022-10-31
Journal: Frontiers in Bioengineering and Biotechnology [Category] COVID-19,

[키워드] acute respiratory distress Admission Antiviral ARDS cause caused Cell Characteristics coronavirus-induced disease 2019 COVID-19 COVID-19 pandemic Cytokine storm Disseminated intravascular coagulation drug edema Effect exacerbated response fibrosis health system immune system immunomodulatory Inflammatory intensive care lung tissue Mesenchymal stromal cells opportunistic Infections other organs patients with COVID-19 Perinatal placental expanded provide reduce Respiratory system safety profile Sepsis severe acute respiratory distress syndrome coronavirus-2 stimulate subject susceptibility Symptom syndrome therapy tissue Treatment Vaccines viral infection
[DOI] 10.3389/fbioe.2020.619980 PMC 바로가기 [Article Type] Bioengineering and Biotechnology

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Randomized Controlled Trial

Published on 2021-01-092022-10-04
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 1:1 95% CI acute respiratory syndrome adjusted age analysed Analysis assigned AstraZeneca AZD1222 blinded both group Brazil calculated ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Clinical research clinical trials Coalition Cohort contribute control group Controlled trial coronavirus Coverage COVID-19 COVID-19 pandemic Cutoff death dose doses Efficacy efficacy analysis enrolled evaluated event finding first dose Follow-up foundation funding hospitalised include Innovation Interaction interim analysis IQR ISRCTN89951424 low dose median Melinda Gate network NIHR nucleic acid amplification occurred Older Oxford participant Participants Poisson regression model randomised randomised controlled trial Randomly Registered risk robust Safe Safety safety profile SARS-CoV-2 second dose seronegative participant severe adverse event severe COVID-19 South South Africa Standard dose subset Swab symptomatic Telle Treatment Trial trials Vaccine vaccine efficacy Valley viral particle
[DOI] 10.1016/S0140-6736(20)32661-1 PMC 바로가기 [Article Type] Randomized Controlled Trial

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

COVID-19 폐렴으로 입원한 환자의 임상 악화에 대한 Tocilizumab 대 표준 치료의 효과: 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-01-012022-09-12
Journal: JAMA Internal Medicine [Category] 임상, 진단,

[키워드] 95% CI age benefit blinded C-reactive protein causes clinical Clinical Center control arm control group coronavirus disease COVID-19 criteria death defined died Disease progression Effect elevated EudraCT evaluate evaluate the effect experimental arm experimental group Fever fraction groups hospital Hospitalized inflammatory phenotype intensive care Intention-to-treat analyses interim analysis interquartile range intravenous tocilizumab Intubated Invasive mechanical ventilation Italy less majority male median Nasopharyngeal swab NCT04346355 Open-label outcome oxygen pandemic Patient patients hospitalized patients with COVID-19 placebo-controlled Pneumonia polymerase chain Prospective protocol radiologic imaging randomization Randomized randomized clinical trial randomized patient receive Retrospective study safety profile second dose shown Stage Standard standard care standard care group Standard of care Standard therapy supportive care the disease therapy Tocilizumab tocilizumab administration Trial Two patient with COVID-19 worsening
[DOI] 10.1001/jamainternmed.2020.6615 PMC 바로가기 [Article Type] Randomized Controlled Trial

Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study

Pentoxifylline은 COVID-19 환자의 혈청 LDH 수준을 감소시키고 림프구 수를 증가시킵니다: 외부 파일럿 연구 결과

Randomized Controlled Trial

Published on 2021-01-012022-09-11
Journal: International immunopharmacology [Category] SARS, 바이오마커, 신약개발, 임상,

[키워드] alveolar epithelial cells Biomarker carried control group COVID-19 COVID-19 treatment decrease e parameters Endothelium epithelial cells Evidence Hospitalization Host immune response immune response Immunomodulatory treatment Immunosuppression IMPROVE increase intubation Lactate lactate dehydrogenase LDH Linear regression model linear regression models lymphocyte Lymphocyte count Lymphocytes Mortality no risk no statistically significant difference open parameter parameters Patient patients with moderate Pentoxifylline pilot study Pragmatic pragmatic randomized controlled trial proportion Randomized Randomized controlled trial receive reduce reduced Result safety profile SARS-COV-2 infection seriousness serum severe COVID-19 severity of COVID-19 Standard therapy standard treatment statistically significant statistically significant difference the disease Treatment treatment of COVID-19
[DOI] 10.1016/j.intimp.2020.107209 PMC 바로가기 [Article Type] Randomized Controlled Trial

Infections and Immunotherapy in Lung Cancer: A Bad Relationship?

Review

Published on 2020-12-222022-10-29
Journal: International Journal of Molecular Sciences [Category] B형 간염, COVID-19, MERS,

[키워드] administration affecting Analysis Antibiotic therapy anticancer Antiretroviral therapy Bacterial infections Cancer cancer patient Clinical practice clinical trial complex correlation COVID-19 described disease Evidence excluded HBV HCV Hepatitis HIV Immune checkpoint inhibitors immune system Immunotherapy impairing implication Infection Infectious disease lung cancer lung cancer patient lung cancer patients management microbiota Mortality Non-small cell lung cancer outcome Patient patient subgroup patients patients treated performed Prognosis prognostic Prospective trial reported retrospective risk of COVID-19 safety profile suggested therapy Thoracic toxicities Treatment trials viral infection viral infections virus with HIV
[DOI] 10.3390/ijms22010042 PMC 바로가기 [Article Type] Review